Inhibiting ack1-mediated phosphorylation of c-terminal src kinase counteracts prostate cancer immune checkpoint blockade resistance

HIGHLIGHTS

• who: Dhivya Sridaran from the (UNIVERSITY) have published the Article: Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance, in the Journal: (JOURNAL) of 16/09/2021
• what: The authors show that the conserved oncogenic tyrosine kinase Activated CDC42 kinase 1 (ACK1) is able to phosphorylate CSK at Tyrosine 18 (pY18), which enhances CSK function, constraining T-cell activation. The WT and Ack1 KO mice used for the experiments were in-bred as described above.
• how: To explore the outcome of the immunoinhibitory activity of ACK1 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.